If you remember the missed dose on the same day, take it as soon as possible. If it is close to the time of your next scheduled dose, skip the missed tablet and continue with your regular once-daily schedule. Do not double the dose.
Velpanat can be taken with antacids that do not contain aluminium or magnesium. Proton-pump inhibitors (e.g., omeprazole) do not significantly affect absorption, so they can be used together. Separate aluminium/magnesium-containing antacids by at least four hours.
For patients with an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m² or higher, no dose adjustment is required. However, severe renal impairment (eGFR < 30) is a relative contraindication because the metabolite of sofosbuvir can accumulate.
Both Velpanat and Harvoni contain a NS5B polymerase inhibitor and an NS5A inhibitor, providing pan-genotypic coverage. The primary difference lies in the specific agents: Harvoni combines ledipasvir with sofosbuvir, while Velpanat combines velpatasvir with sofosbuvir. Clinical outcomes are comparable, but the choice may depend on physician preference, drug-interaction profiles, or regional availability.
Yes. Baseline HCV RNA, liver function, and renal function tests are required before starting therapy. During treatment, a repeat HCV RNA test at week 4 helps confirm viral suppression, and liver enzymes are usually checked once mid-course. A final HCV RNA test at 12 weeks post-treatment confirms cure (SVR).
Moderate alcohol intake does not interfere with Velpanat’s efficacy, but heavy drinking can worsen liver damage and counteract the benefits of therapy. Discuss your alcohol consumption with your healthcare provider to determine a safe limit.
Velpanat may have moderate interactions with certain HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors, potentially reducing velpatasvir levels. Your prescriber can review your HIV regimen and may adjust doses or select alternative agents to avoid reduced effectiveness.
Seek immediate medical attention if you develop severe dizziness, fainting, a rapid drop in heart rate (bradycardia), significant yellowing of the skin or eyes (jaundice), or any signs of allergic reaction such as rash, swelling, or difficulty breathing.
Cure, defined as sustained virologic response, is assessed 12 weeks after finishing the 12-week course. If HCV RNA remains undetectable at that point, the infection is considered cured.
If you have underlying liver disease, especially cirrhosis, regular monitoring and possibly other supportive treatments (e.g., for portal hypertension) may continue. Otherwise, no antiviral therapy is required after confirmed SVR.
Velpanat is an antiviral medication that combines the active ingredients sofosbuvir (400 mg) and velpatasvir (100 mg) in a single tablet formulation. It belongs to the class of direct-acting antivirals (DAAs) used to treat chronic hepatitis C virus (HCV) infection. In the United Kingdom, Velpanat is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The tablet is designed for oral administration and is supplied in the strength 400 mg/100 mg.
Together, the two agents provide a pan-genotypic attack on HCV, meaning they are active against all six major genotypes (1-6). The combined effect leads to rapid declines in viral load, typically achieving undetectable levels within weeks of starting therapy. Onset of action is within the first dose, with peak plasma concentrations reached in 3-5 hours. The drugs are primarily eliminated unchanged in the urine (sofosbuvir) and feces (velpatasvir).
The medication is intended to achieve a sustained virologic response (SVR), which is considered a cure of HCV infection when viral RNA remains undetectable 12 weeks after treatment completion.
No robust, peer-reviewed evidence currently supports off-label use of the sofosbuvir/velpatasvir combination for indications outside chronic hepatitis C. Consequently, this section is omitted.
These reactions are usually mild, transient, and resolve without intervention. Maintaining adequate hydration and taking the tablet with food can lessen gastrointestinal discomfort.
Major interactions (avoid co-administration):
Strong CYP3A4 inducers such as rifampicin, carbamazepine, phenytoin, and St. John’s Wort can reduce velpatasvir levels, risking treatment failure.
Amiodarone - May cause serious bradycardia; concurrent use requires cardiac monitoring and possible alternative therapy.
Moderate interactions (require dose adjustment or monitoring):
HIV protease inhibitors (e.g., darunavir, lopinavir) and non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz) can modestly lower velpatasvir concentrations.
Antacids containing aluminium or magnesium may reduce absorption of velpatasvir; separate administration by at least 4 hours is recommended.
Food and Lifestyle Interactions
Velpanat can be taken with or without food; a high-fat meal may slightly increase velpatasvir exposure but does not affect efficacy.
No known interaction with alcohol, but excessive intake can worsen underlying liver disease.
This article provides educational information about Velpanat and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
